{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T11:46:59Z","timestamp":1769082419651,"version":"3.49.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.leukres.2017.07.006","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T04:16:28Z","timestamp":1500956188000},"page":"89-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Clinical characteristics and prognosis of primary Waldeyer's ring and lymph node diffuse large B-cell lymphoma in the rituximab era"],"prefix":"10.1016","volume":"60","author":[{"given":"Xiao-mei","family":"Jing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-rui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang-kun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-chuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-feng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2017.07.006_bib0005","first-page":"iv141","article-title":"The relative frequencies of lymphoma subtypes in China: a nationwide study of 10002 cases by the Chinese Lymphoma Study Group","volume":"22","author":"Li","year":"2011","journal-title":"Ann. Oncol."},{"issue":"April (12)","key":"10.1016\/j.leukres.2017.07.006_bib0010","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1200\/JCO.2005.07.155","article-title":"Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin","volume":"23","author":"L\u00f3pez-Guillermo","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"February (1)","key":"10.1016\/j.leukres.2017.07.006_bib0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/COC.0b013e318261084b","article-title":"Clinical disparity and favorable prognoses for patients with Waldeyer ring extranodal nasal-type NK\/T-cell lymphoma and diffuse large B-cell lymphoma","volume":"37","author":"Wu","year":"2014","journal-title":"Am. J. Clin. Oncol."},{"issue":"March","key":"10.1016\/j.leukres.2017.07.006_bib0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bcmd.2015.12.004","article-title":"Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites","volume":"57","author":"Wang","year":"2016","journal-title":"Blood Cells Mol Dis."},{"issue":"March (3)","key":"10.1016\/j.leukres.2017.07.006_bib0025","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s12185-013-1282-3","article-title":"Prognostic value of Waldeyer's ring involvement of diffuse large B-cell lymphoma treated with R-CHOP","volume":"97","author":"Oh","year":"2013","journal-title":"Int. J. Hematol."},{"issue":"Suppl. 5, September","key":"10.1016\/j.leukres.2017.07.006_bib0030","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann. Oncol."},{"issue":"September (12)","key":"10.1016\/j.leukres.2017.07.006_bib0035","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"January (1)","key":"10.1016\/j.leukres.2017.07.006_bib0040","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2002-04-1286","article-title":"Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma","volume":"101","author":"Colomo","year":"2003","journal-title":"Blood"},{"issue":"January (1)","key":"10.1016\/j.leukres.2017.07.006_bib0045","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"November (21)","key":"10.1016\/j.leukres.2017.07.006_bib0050","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1002\/cncr.24557","article-title":"Diffuse large B-cell lymphoma: clinical characterization and prognosis of Waldeyer ring versus lymph node presentation","volume":"115","author":"Qi","year":"2009","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.leukres.2017.07.006_bib0055","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"August","key":"10.1016\/j.leukres.2017.07.006_bib0060","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.leukres.2016.05.004","article-title":"Efficacy and tolerance of pegaspargase, gemcitabine and oxaliplatin with sandwiched radiotherapy in the treatment of newly-diagnosed extranodal nature killer (NK)\/T cell lymphoma","volume":"47","author":"Jing","year":"2016","journal-title":"Leuk. Res."},{"issue":"November (11)","key":"10.1016\/j.leukres.2017.07.006_bib0065","first-page":"1860","article-title":"Report of the committee on Hodgkin\u2019s disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res."},{"issue":"September (17)","key":"10.1016\/j.leukres.2017.07.006_bib0070","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1002\/cncr.27381","article-title":"Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era","volume":"118","author":"Takahashi","year":"2012","journal-title":"Cancer"},{"issue":"December (12)","key":"10.1016\/j.leukres.2017.07.006_bib0075","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1093\/annonc\/mds150","article-title":"Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study","volume":"23","author":"de Leval","year":"2012","journal-title":"Ann. Oncol."},{"issue":"January (4)","key":"10.1016\/j.leukres.2017.07.006_bib0080","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"May (5)","key":"10.1016\/j.leukres.2017.07.006_bib0085","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol."},{"issue":"February (2)","key":"10.1016\/j.leukres.2017.07.006_bib0090","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol."},{"issue":"June (6)","key":"10.1016\/j.leukres.2017.07.006_bib0095","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00277-011-1375-0","article-title":"Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group","volume":"91","author":"Li","year":"2012","journal-title":"Ann. Hematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261730471X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261730471X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T20:17:45Z","timestamp":1530130665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261730471X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":19,"alternative-id":["S014521261730471X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.07.006","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics and prognosis of primary Waldeyer's ring and lymph node diffuse large B-cell lymphoma in the rituximab era","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}